Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism
暂无分享,去创建一个
L. Cavallari | S. Patel | Hyunyoung Jeong | H Takahashi | E. Nutescu | K. Drozda | Y Liu | H Jeong | K Drozda | S R Patel | N L Shapiro | E A Nutescu | L H Cavallari | H. Jeong | Harumi Takahashi | N. Shapiro | Shitalben R. Patel | Y. Liu | Yong Liu | Yong Liu | H. Takahashi | L. Cavallari
[1] J. Crawford,et al. Simplification of drug dosage calculation by application of the surface area principle. , 1950, Pediatrics.
[2] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[3] William J. Jusko,et al. Berichten , 2005, Pharmaceutisch weekblad.
[4] L. Wienkers,et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.
[5] W. Trager,et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.
[6] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[7] H. Echizen,et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[8] H. Echizen,et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes , 1998, Clinical pharmacology and therapeutics.
[9] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[10] H. Yamazaki,et al. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[11] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[12] R. Kim,et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.
[13] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[14] E. Spina,et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.
[15] H. Mohrenweiser,et al. Discovery of new potentially defective alleles of human CYP2C9. , 2004, Pharmacogenetics.
[16] U. Yasar,et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. , 2004, Clinical pharmacology and therapeutics.
[17] T. Langaee,et al. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. , 2004, Clinical chemistry.
[18] J. Gala,et al. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population , 2005, Pharmacogenetics and genomics.
[19] D. Rock,et al. CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles , 2006, Drug Metabolism and Disposition.
[20] Julie A. Johnson,et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.
[21] Timothy S Tracy,et al. Polymorphic Variants of CYP2C9: Mechanisms Involved in Reduced Catalytic Activity , 2007, Molecular Pharmacology.
[22] G. Mcgwin,et al. Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin , 2008, Clinical pharmacology and therapeutics.
[23] Mark Crowther,et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[24] J. Lindh,et al. Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis , 2009, European Journal of Clinical Pharmacology.
[25] R. Beyth,et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[26] C. Thorn,et al. Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.
[27] J. Hirsh,et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[28] N. Limdi,et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. , 2008, Pharmacogenomics.
[29] J. Halperin,et al. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.
[30] T. Miyata,et al. Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects , 2009, Drug Metabolism and Disposition.
[31] T. Langaee,et al. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.
[32] U. Fuhr,et al. Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. , 2010, Current drug metabolism.
[33] L. Cavallari,et al. Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African‐American Patients , 2011, Pharmacotherapy.
[34] A. Krause,et al. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. , 2011, Pharmacogenomics.
[35] D. Nicolae,et al. The Missing Association: Sequencing‐Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans , 2011, Clinical pharmacology and therapeutics.